A Phase III, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06973187

Study #:
STUDY00162033

Start Date:
Feb 05, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06973187

View Complete Trial Details & Eligibility at ClinicalTrials.gov